SysGen Seminar – Sean Grimmond – 11th November, 2016

Decoding Cancer’s Root Causes, Drivers, and Achilles’ heels though whole genome analysis

Prof Sean Grimmond
Centre for Cancer Research, University of Melbourne

Friday 11th November
ESJ King Theatre, Medical Building, The University of Melbourne

AbstractIt is now well established that a cancer’s mutational burden drives its formation, influences its progression and can dictate its sensitivity to chemotherapy. Professor Grimmond leads Australia’s contribution to the International Caner Genome Consortium and has sort to resolve the root causes of somatic mutation, the role of germline predisposition, what genes / events create the oncogenic switch, and to use these combined insights to pursue new anti-cancer therapies many challenging cancers including pancreatic adenocarcinoma, neuroendocrine tumours, ovarian cancer, oesophageal cancer, melanoma and refractory Leukemias. This presentation will show the breadth of mutational mechanisms and driver mutations at play, even in morphologically identical tumours and this is forming the foundations for genomic pathology and personalized medicine.

Professor Grimmond obtained his PhD in pathology from the University of Queensland. He is a founding scientific fellow in The Royal College of Pathologists of Australasia. Previous appointments include the chair of medical genomics at the University of Glasgow, co-director of the Scottish Genomes Partnership, a professor of genetics at the University of Queensland, and founding director of the Queensland Centre for Medical Genomics. Over the past 8 years, Sean has pioneered whole-genome and transcriptome analysis of cancer patients, led Australia’s International Cancer Genome Consortium efforts into pancreatic, neuroendocrine and ovarian cancer, and contributed cohort-based mutational landscape studies in melanoma and oesophageal cancer. These studies have been used to resolve the mutagenic processes, driver mutations, molecular taxonomies, and potential vulnerabilities open to therapeutic exploitation in these cancer types. His current research is firmly focused on real-time omic analysis of recalcitrant cancers, testing the value of personalised therapies, and further cancer genome discovery.

Enquiries: Andrew Siebel (